These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7933219)

  • 1. Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology.
    Schmittgen TD; Weaver JM; Badalament RA; Wientjes MG; Klein EA; Young DC; Au JL
    J Urol; 1994 Nov; 152(5 Pt 1):1632-6. PubMed ID: 7933219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of mitomycin C in cultured human bladder tumors.
    Schmittgen TD; Wientjes MG; Badalament RA; Au JL
    Cancer Res; 1991 Aug; 51(15):3849-56. PubMed ID: 1906778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures.
    Yen WC; Schmittgen T; Au JL
    Pharm Res; 1996 Dec; 13(12):1887-91. PubMed ID: 8987090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCNA immunostaining as a valid alternative to tritiated thymidine-autoradiography to detect proliferative cell fraction in transitional cell bladder carcinomas.
    Lavezzi AM; Terni L; Matturri L
    In Vivo; 2000; 14(3):447-51. PubMed ID: 10904880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Bromodeoxyuridine incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder.
    Waldman FM; Carroll PR; Cohen MB; Kerschmann R; Chew K; Mayall BH
    Mod Pathol; 1993 Jan; 6(1):20-4. PubMed ID: 8093979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional heterogeneity and pharmacodynamics in human solid tumor histoculture.
    Weaver JR; Wientjes MG; Au JL
    Cancer Chemother Pharmacol; 1999; 44(4):335-42. PubMed ID: 10447582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
    Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
    Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic value of proliferating cell nuclear antigen in transitional cell carcinoma of the urinary bladder.
    Chen G; Lin MS; Li RC
    Urol Res; 1997; 25(1):25-30. PubMed ID: 9079742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cultured human bladder tumors for pharmacodynamic studies.
    Schmittgen TD; Au JL; Wientjes MG; Badalament RA; Drago JR
    J Urol; 1991 Jan; 145(1):203-7. PubMed ID: 1898521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of doxorubicin in human bladder tumors.
    Gan Y; Wientjes MG; Badalament RA; Au JL
    Clin Cancer Res; 1996 Aug; 2(8):1275-83. PubMed ID: 9816297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder.
    Ogura K; Fukuzawa S; Habuchi T; Ogawa O; Yoshida O
    Int J Urol; 1997 Nov; 4(6):561-6. PubMed ID: 9477184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.
    Pantazopoulos D; Ioakim-Liossi A; Karakitsos P; Aroni K; Kakoliris S; Kanavaros P; Kyrkou KA
    Anticancer Res; 1997; 17(1B):781-6. PubMed ID: 9066620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Growth fractions of bladder cancer determined by proliferating cell nuclear antigen immunostaining].
    Kuroda H; Yasunaga Y; Takatera H; Fujioka H; Ohnishi A; Tsujimoto M
    Hinyokika Kiyo; 1994 May; 40(5):379-82. PubMed ID: 7912881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunohistochemical investigation of proliferating cell nuclear antigen in bladder cancer].
    Sumiyoshi Y; Inoue Y; Akiyama M
    Nihon Hinyokika Gakkai Zasshi; 1993 Sep; 84(9):1643-8. PubMed ID: 8105131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of p53 and proliferating cell nuclear antigen (PCNA) in bladder cancer: positive immunostaining and radiosensitivity.
    Ogura K; Habuchi T; Yamada H; Ogawa O; Yoshida O
    Int J Urol; 1995 Nov; 2(5):302-8. PubMed ID: 8749948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
    Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL
    Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C.
    Verma A; Degrado J; Hittelman AB; Wheeler MA; Kaimakliotis HZ; Weiss RM
    BJU Int; 2011 Apr; 107(7):1154-61. PubMed ID: 20735383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
    Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X
    Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histocultures of human prostate tissues for pharmacologic evaluation.
    Wientjes MG; Pretlow TG; Badalament RA; Burgers JK; Au JL
    J Urol; 1995 Apr; 153(4):1299-302. PubMed ID: 7532726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.